Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma.

ABSTRACT: Synovial sarcoma (SS) is an aggressive mesenchymal malignancy that is refractory to treatment with immune checkpoint inhibitor-based therapy. We investigated the infiltrating T cell immune status in archived patient samples and tested the efficacy of an oncolytic measles virus (MV) encoding the secretory form of the neutrophil-activating protein (s-NAP) in SS. To assess T cell infiltration, we performed T cell receptor (TCR) sequencing on archived formalin-fixed, paraffin-embedded specimens, comparing SS with undifferentiated pleomorphic sarcoma (UPS), a highly immunogenic sarcoma. Patients with SS had significantly lower T cell infiltration, reduced clonality, and higher TCR diversity than those with UPS. No differences were observed in the T cell repertoire between monophasic and biphasi

SUBMITTER: Robinson SI 

PROVIDER: S-EPMC12605261 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature